American Society of Hirudotherapy

Cancer-Associated Splanchnic Vein Thrombosis

Review published in Seminars in thrombosis and hemostasis (2021)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentCohen et al. · Seminars in thrombosis and hemostasis, 2021

Abstract

Splanchnic vein thrombosis (SVT), which includes portal, mesenteric, and splenic vein thrombosis and the Budd-Chiari syndrome, is an infrequent manifestation of venous thromboembolism (VTE). Like typical site VTE, SVT is also frequently associated with cancer, particularly intra-abdominal solid malignancies and myeloproliferative neoplasms (MPNs). The clinical presentation of SVT is nonspecific. Symptoms may be related to the underlying malignancy, and thrombosis is incidentally diagnosed by imaging studies for cancer staging or follow-up in a substantial proportion of cases. The occurrence of SVT predicts worse prognosis in patients with liver or pancreatic cancer and, not uncommonly, SVT may precede the diagnosis of cancer. Therefore, the occurrence of an apparently unprovoked SVT should prompt careful patient evaluation for the presence of an underlying malignancy or MPN. Cancer patients carry a high risk of VTE extension and recurrence and long-term anticoagulant treatment is suggested in the absence of high risk of bleeding. Either LMWH or direct oral anticoagulants (DOACs) are suggested for the treatment of patients with cancer-related SVT, although limited experience is available on the use of DOACs in these settings. Vitamin K antagonists (VKAs) are suggested for the short and long-term treatment of SVT associated with MPN. This review outlines the epidemiological aspects, pathogenesis, risk factors, and diagnosis of cancer-associated SVT, and addresses questions regarding the management of this challenging condition.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsHeparin, Low-Molecular-WeightHumansNeoplasmsVenous ThromboembolismVenous Thrombosis

Summary

This review of cancer-associated splanchnic vein thrombosis covers epidemiology, risk factors, diagnosis, and management, suggesting LMWH or direct oral anticoagulants for cancer-related cases and vitamin K antagonists when thrombosis is associated with myeloproliferative neoplasms.

Context

This review outlines the epidemiology, pathogenesis, risk factors, diagnosis, and management of cancer-associated splanchnic vein thrombosis (SVT), discussing anticoagulation options including LMWH, direct oral anticoagulants, and vitamin K antagonists for this challenging condition. Hirudin is an anticoagulant and leech therapy provides anticoagulation. No leeches, hirudin products, or hirudotherapy are mentioned.

Citation

Reference (Vancouver style)

Cohen O, Caiano LM, Tufano A, Ageno W. Cancer-Associated Splanchnic Vein Thrombosis. Semin Thromb Hemost. 2021;47(8):931-941. doi:10.1055/s-0040-1722607. PMID: 34116580

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.